Bloomberg - The drugmaker said in a CNW statement that final results of Phase I/II multiple-dose trials of Exendin-4 show that the treatment for Type 2 diabetes was ``well tolerated'' and ``effective in lowering blood glucose'' if taken in the tested dosages ...
